Gearbox Biosciences

High-end biotechnology services and goods are provided by the Icosagen Group, a contract research organisation and technology developer for the biopharmaceutical and biotechnology sectors of industry and academia. The business offers services such as protein, antibody, and VLP manufacturing. Products include ELISA kits, transfection reagent, proteins, antibodies, and DNA/RNA isolation Additionally, it provides quality assurance services like FITkit for checking latex allergens and food microbiological testing services. The Icosagen Group takes part in numerous national and international research initiatives, such as INTENSO, MAARS, and EURIPRED.

Antegenes’ novel genetic tests assess a patient’s personal cancer risks, and include clinical recommendations for personalized cancer prevention. The tests are based on innovative polygenic risk score technology which helps to clarify a person’s genetic predispositions to cancer. It therefore allows for more accurate prevention and early detection measures – crucial in the fight with cancer. The tests are currently being used to determine the genetic risk for four cancers: breast cancer, prostate cancer, colon cancer, and skin melanoma.

Decomer Technology is develops a novel water-soluble and edible packaging material and products thereof.

Gelatex is a Techstars-backed materials technology company that invented the fastest technology for producing bio-based nanofibers on a large scale. It is a platform technology that enables faster and up to 100 cheaper nanofiber production for applications like 3D scaffolds for tissue engineering, cultured meat, bio-based filters, eco-friendly leather-like textile, energy storage, wound care, and many more. The technology is patent-pending and the machinery fully functional. The company was founded in 2016 and until COVID-19 pandemic developed eco-friendly leather-like textile from gelatin nanofibers, using this nanofiber production technology as part of the process. COVID-19 was a trigger to understand the wider potential of the technology which then led to pivot. The company is based in Estonia and holding incorporated in UK (2019).

ImmunitoAI is a life sciences (biotech) platform that leverages AI to revolutionize antibody discovery & therapeutics.

AI Metrics is an early stage company creating transformational image analysis technology that positions radiologists to be the most efficient, valuable clinicians in the patient care continuum

Luminate Medical develops a medical device designed to prevent hair loss during chemotherapy. Luminate Medical recognises that hair is an essential element of personality and self-esteem, and is dedicated to using the latest advances in medical technology to protect this.

Hermes Biosciences describes a benchtop, hands-off extracellular vesicle isolation system designed to purify exosomes quickly, efficiently.

InvenireX is a biotech company that provides molecular diagnostics services.

Chromologics is a company that creates new and original food colorings utilizing natural ingredients. Derived from the Technical University of Denmark, this Danish biotech spin-out has established a biotech framework that employs fungi to generate exceptional and eco-friendly colorants.

Artios is an independent DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. Established in May 2016, the Company is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. Artios is building a pipeline of next-generation DDR programs, including through a unique partnership with Cancer Research Technology (CRT), the development and commercialization arm of Cancer Research UK (CRUK), and with leading DNA repair researchers worldwide. The Company’s investors include SV Life Sciences, Merck Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures. Artios is based at the Babraham Institute in Cambridge, UK.

Bambusa Therapeutics is a biotechnology company that specializes in the development of bispecific antibodies.